Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever.
[familial mediterranean fever]
Herein
,
we
reported
our
experience
in
colchicine-resistant
familial
Mediterranean
fever
(
FMF
)
patients
who
are
treated
with
anti-interleukin-
1
(
IL
-
1
)
drugs
.
A
retrospective
review
of
medical
records
of
anti-
IL
-
1
recipients
was
performed
.
The
main
clinical
characteristics
of
these
patients
and
the
evolution
after
anti-
IL
-
1
were
recorded
.
There
were
20
patients
(
11
male
[
M
]
and
9
female
[
F
]
)
.
Despite
regular
colchicine
treatment
,
median
number
of
attacks
per
month
and
per
year
was
1
(
1
-
4
)
and
12
(
4
-
50
)
,
respectively
.
Twelve
patients
were
receiving
anakinra
,
and
eight
patients
were
treated
with
canakinumab
.
The
number
of
monthly
and
yearly
attacks
after
IL
-
1
treatment
was
significantly
decreased
after
the
biologic
agent
(
p
 
<
 
0
.
05
)
.
One
patient
did
not
respond
to
the
treatment
,
and
one
patient
developed
serious
infection
during
anti-
IL
-
1
.
We
also
observed
a
significant
decrease
in
proteinuria
in
the
amyloidosis
complicated
FMF
patients
.
Anti-
IL
-
1
targeting
drugs
seem
safe
and
effective
therapies
in
colchicine-resistant
FMF
.
